| Literature DB >> 27406872 |
Jun-Dong Wu1, Wen-He Huang1, Si-Qi Qiu1, Li-Fang He1, Cui-Ping Guo1, Yong-Qu Zhang1, Fan Zhang2, Guo-Jun Zhang1,2.
Abstract
Breast reconstruction with transverse rectus abdominis myocutaneous (TRAM) flap is challenging in patients with low midline abdominal scar. In this study, we aimed to investigate the clinical feasibility of immediate breast reconstruction using single-pedicle TRAM (SP-TRAM) flaps in patients with low midline abdominal scar. There were 4 strict selection criteria: 1) presence at least 3 perforators on the pedicle side; 2) perforators with regional average flow velocity of >20 cm/s; 3) upper edge of the abdominal scar at least 4 cm from the umbilicus; and 4) scar age >1 year. Eight breast cancer patients with low midline abdominal scar (scar group) and 20 without (control group) underwent immediate breast reconstruction with SP-TRAM flaps consisting of zone I and III and zone II tissues. Flap complications, donor-site complications, and cosmetic results were compared between the two groups. All flaps survived and both groups presented similar flap and donor site complications, including fat necrosis, seroma, hematoma, infection, delayed wound healing, and abdominal hernia, and patients in both groups had similar aesthetic results (p > 0.05). Thus, the study demonstrated that breast reconstruction using SP-TRAM flap was a safe approach in carefully selected patients with low midline abdominal scar.Entities:
Mesh:
Year: 2016 PMID: 27406872 PMCID: PMC4942775 DOI: 10.1038/srep29580
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Patient characteristics.
| Demographics | Scar Group (n = 8) | Control Group (n = 20) | t | χ2 | |
|---|---|---|---|---|---|
| Mean age (yr) | 42.3 ± 6.6 | 38.4 ± 5.3 | −1.64 | 0.11 | |
| BMI (kg/m2) | 24.1 ± 2.4 | 22.2 ± 2.3 | −1.95 | 0.06 | |
| Diabetes | 0 (0.0%) | 1 (5.0%) | – | 1.00 | |
| Smokers | 1 (12.5%) | 0 (0.0%) | – | 0.29 | |
| NAC | 1 (12.5%) | 1 (5.0%) | – | 0.50 | |
| PR | 0 (0.0%) | 0 (0.0%) | – | ||
| Histology | – | 0.79 | |||
| DCIS | 0 (0.0%) | 2 (10.0%) | |||
| LCIS | 0 (0.0%) | 1 (5.0%) | |||
| IDC | 7 (87.5%) | 15 (75.0%) | |||
| ILC | 1 (12.5%) | 0 (0.0%) | |||
| mucinous | 0 (0.0%) | 1 (5.0%) | |||
| Medullary | 0 (0.0%) | 1 (5.0%) | |||
| Histological grade | – | 0.27 | |||
| 1 | 2 (25.0%) | 1 (5.0%) | |||
| 2 | 4 (50.0%) | 7 (35.0%) | |||
| 3 | 2 (25.0%) | 9 (45.0%) | |||
| 0 (0.0%) | 3 (15.0%) | ||||
| pTNM stage | – | 0.38 | |||
| 0 | 0 (0.0%) | 3 (15.0%) | |||
| I | 2 (25.0%) | 3 (15.0%) | |||
| II | 5 (62.5%) | 14 (70.0%) | |||
| III | 1 (12.5%) | 0 (0.0%) | |||
| Molecular subtype | – | 0.76 | |||
| Luminal A | 2 (25.0%) | 6 (30.0%) | |||
| Luminal B1 | 4 (50.0%) | 5 (25.0%) | |||
| Luminal B2 | 0 (0.0%) | 3 (15.0%) | |||
| HER-2 overexpression | 1 (12.5%) | 2 (10.0%) | |||
| Triple negative | 1 (12.5%) | 4 (20.0%) |
Note: Fisher’s exact tests.
Abbreviations: BMI, body mass index; NAC, neoadjuvant chemotherapy; PR, preoperative radiotherapy; DCIS, Ductal carcinoma in situ; LCIS, Lobular carcinoma in situ; IDC, Invasive ductal carcinoma; ILC, Invasive lobular carcinoma.
Figure 1(A) A 37-year-old woman with invasive ductal carcinoma in the right outer quadrant close to the areola. A1: Location and peak systolic flow velocities of the perforators were assessed with pre-operative color-flow duplex ultrasound scanning. A2: The patient had a previous low midline abdominal scar and breast reconstruction with a single-pedicle transverse rectus abdominis myocutaneous (SP-TRAM) flap was planned. A3: The patient underwent mastectomy with immediate reconstruction using single-pedicle TRAM flap and was followed for 20 months. (B) A 50-year-old woman with invasive ductal carcinoma in the right central quadrant. B1: The perforator locations and peak systolic flow velocities were detected by pre-operative color-flow duplex scanning. B2: The patient had previous low midline abdominal scar and was scheduled for mastectomy with immediate SP-TRAM flap breast reconstruction. B3: The same patient at 6 months after surgery.
Flap-related complications.
| Scar group (n = 8) | Control group (n = 20) | χ2 | ||
|---|---|---|---|---|
| Overall | 2 (25.0%) | 4 (20.0%) | 1.00 | |
| Completely flap loss | 0 (0.0%) | 0 (0.0%) | − | |
| Partial flap loss | 1 (12.5%) | 1 (5.0%) | 0.50 | |
| Fat necrosis | 1 (12.5%) | 3 (15.0%) | 1.00 | |
| Seroma | 0 (0.0%) | 0 (0.0%) | – | |
| Hematoma | 0 (0.0%) | 0 (0.0%) | – | |
| Infection | 0 (0.0%) | 0 (0.0%) | – |
Note: Fisher’s exact tests.
Donor site complications.
| Scar group (n = 8) | Control group (n = 20) | χ2 | ||
|---|---|---|---|---|
| Overall | 3 (37.5%) | 4 (20.0%) | 0.37 | |
| Seroma | 0 (0.0%) | 0 (0.0%) | − | |
| Infection | 1 (12.5%) | 1 (5.0%) | 0.50 | |
| Fat necrosis | 1 (12.5%) | 1 (5.0%) | 0.50 | |
| Hematoma | 0 (0.0%) | 1 (5.0%) | 1.00 | |
| Delayed wound healing | 1 (12.5%) | 1 (5.0%) | 0.50 | |
| Hernia/bulge | 0 (0.0%) | 0 (0.0%) | − |
Note: Fisher’s exact tests.
Frequency of perforators by side and zone in 8 patients (scar group) (%).
| Zone I | Zone II | Zone III | Zone IV | Total | |
|---|---|---|---|---|---|
| Right | 10 | 12 | 10 | 7 | 39 |
| Left | 9 | 13 | 10 | 6 | 38 |
| Total | 19 | 25 | 20 | 13 | 77 |
| Percent | 24.7 | 32.5 | 26.0 | 16.9 |
Peak systolic flow velocity in TRAM flap perforators in 8 patients (scar group)(cm/s).
| Zone I | Zone II | Zone III | Zone IV | |||||
|---|---|---|---|---|---|---|---|---|
| Right | Left | Right | Left | Right | Left | Right | Left | |
| Minimum | 6.2 | 5.8 | 5.4 | 5.0 | 4.5 | 4.5 | 3.8 | 4.2 |
| Maximum | 42.5 | 42.8 | 52.5 | 45.4 | 40.4 | 38.5 | 21.3 | 10.4 |
| Mean Flow | 20.9 | 22.3 | 25.5 | 21.8 | 18.4 | 14.2 | 10.3 | 8.1 |
TRAM flap: transverse rectus abdominis myocutaneous flap.